Welcome to our dedicated page for ZEAL news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on ZEAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZEAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZEAL's position in the market.
Zealand Pharma announced positive results from the Phase 3 EASE 1 trial of glepaglutide, a treatment for Short Bowel Syndrome (SBS). The trial demonstrated that glepaglutide significantly reduced weekly parenteral support volume by an average of 5.13 Liters/week over 24 weeks, meeting the primary endpoint. Notably, 66% of patients on the treatment experienced a clinically meaningful response, and 9 patients were weaned off parenteral support entirely. The treatment was well-tolerated, with minimal adverse events reported. Upcoming trials, EASE 2 and EASE 3, are expected to provide more insights.
Zealand Pharma presented Phase 2 clinical trial data for BI 456906 at the 58th EASD Annual Meeting, demonstrating a significant HbA1c reduction of up to -1.88% at week 16 in type 2 diabetes patients. This dual glucagon/GLP-1 receptor agonist outperformed semaglutide, which showed a -1.47% reduction. The study focused on multiple dosing and indicated potential benefits for obesity and NASH. Adverse events included gastrointestinal disorders, common in GLP-1 treatments. The next results on bodyweight changes are anticipated at Obesity Week 2022.
Zealand Pharma announced positive results from the Phase 3 trial of dasiglucagon for treating congenital hyperinsulinism (CHI) in infants. The trial demonstrated that dasiglucagon significantly reduced the need for intravenous glucose and allowed most participants to discontinue its use. In Part 1, the mean glucose infusion rate was reduced by 55%, and Part 2 showed that 10 out of 12 infants could stop IV glucose. No serious adverse events were reported, positioning dasiglucagon as a promising new treatment option. Zealand aims to submit a New Drug Application in 2023.
Zealand Pharma (Nasdaq: ZEAL) announced the granting of 19,796 warrants to employees in Denmark as part of its incentive scheme to attract and retain talent. The warrants allow for subscription to new shares, representing 0.04% of the company's total share capital, at an exercise price of DKK 141.0. Valued at DKK 1.4 million, these warrants will vest after three years and can be exercised during specific windows until September 2032. The initiative aligns employee interests with those of shareholders.
Zealand Pharma will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 12:20 p.m. ET. This event will feature a fireside chat and will be broadcast live via a webcast available on the company's website. Zealand Pharma is a biotechnology firm focused on developing peptide-based medicines, with over 10 drug candidates in clinical development. The company has collaborations with Boehringer Ingelheim and AstraZeneca to enhance patient access to its investigational agents.
Zealand Pharma has entered a global license and development agreement with Novo Nordisk to commercialize ZEGALOGUE® (dasiglucagon) for injection, aimed at treating severe hypoglycemia in diabetes patients. Zealand's initial payment is DKK 25 million, with potential total milestone payments reaching DKK 290 million, along with tiered royalties on global net sales. Zealand retains all non-licensed IP rights to other dasiglucagon candidates. This partnership bolsters Zealand's strategy to foster commercial alliances and prioritize research and development.
Zealand Pharma (NASDAQ: ZEAL) announced on August 31, 2022, the latest total of shares and voting rights as per the Danish Capital Markets Act. The company’s total number of shares stands at 46,530,384, with a corresponding voting right count of 46,530,384 as well. This information follows the recent increase in share capital due to employee warrant exercises. Zealand Pharma, based in Copenhagen, focuses on developing peptide-based medicines, with over 10 drug candidates in clinical development.
Zealand Pharma A/S has appointed Henriette Wennicke as its new Chief Financial Officer, effective November 1, 2022. With extensive experience in finance and healthcare, Wennicke was previously Vice President at GN Store Nord and has a decade-long background at Novo Nordisk. The CEO, Adam Steensberg, expressed enthusiasm about her joining at a crucial time for the company, focused on advancing its peptide-based therapeutic pipeline. Wennicke succeeds Matthew Dallas, who is leaving at the end of August.
Zealand Pharma has announced an increase in share capital due to the exercise of employee warrants. This resulted in the issuance of 3,874 new shares at an exercise price of DKK 100.80 each, yielding total proceeds of DKK 390,500. The share capital will rise to nominal DKK 46,530,384. These new shares will confer rights to dividends and one vote at general meetings. The amendment to the Articles of Association associated with this capital increase has been registered with the Danish Business Authority.
Zealand Pharma reported its financial results for the first half of 2022, highlighting a revenue of DKK 43.5 million (USD 6.1 million) compared to DKK 42.3 million (USD 6.8 million) in H1 2021. The company experienced net operating expenses of DKK 502.6 million (USD 70.2 million), down from DKK 582.4 million (USD 93.1 million). Zealand's cash reserves stood at DKK 864.4 million (USD 120.7 million) as of June 30, 2022. Key strategic accomplishments included the sale of the V-Go device and significant R&D progress, positioning Zealand for future growth.
